Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Multi-Center Phase III Study to Evaluate MALG, a Novel Malathion 0.05%Formulation, for the Control of Head Lice in Pediatric and Adult Subjects With Pediculosis Capitis

NCT00244439 is registered in ClinicalTrials.gov with Sun Pharmaceutical Industries, Inc. as lead sponsor.

NCT NCT00244439
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00244439 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Multi-Center Phase III Study to Evaluate MALG, a Novel Malathion 0.05%Formulation, for the Control of Head Lice in Pediatric and Adult Subjects With Pediculosis Capitis
Lead sponsor
Sun Pharmaceutical Industries, Inc.
Phase
Phase 3
Overall status
Completed
Start date
December 31, 2005
Completion date
December 31, 2006
Enrollment
360 (actual)
Sites
6

Conditions

As the registry lists them; a condition with its own page is linked.

lice infestations